KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Total Non-Current Liabilities: 2019-2025

Historic Total Non-Current Liabilities for Royalty Pharma (RPRX) over the last 4 years, with Sep 2025 value amounting to $9.2 billion.

  • Royalty Pharma's Total Non-Current Liabilities rose 18.58% to $9.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.2 billion, marking a year-over-year increase of 18.58%. This contributed to the annual value of $7.9 billion for FY2024, which is 24.96% up from last year.
  • According to the latest figures from Q3 2025, Royalty Pharma's Total Non-Current Liabilities is $9.2 billion, which was up 10.42% from $8.4 billion recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's Total Non-Current Liabilities registered a high of $9.2 billion during Q3 2025, and its lowest value of $6.3 billion during Q3 2023.
  • In the last 3 years, Royalty Pharma's Total Non-Current Liabilities had a median value of $7.8 billion in 2024 and averaged $7.5 billion.
  • In the last 5 years, Royalty Pharma's Total Non-Current Liabilities decreased by 13.62% in 2023 and then grew by 24.96% in 2024.
  • Royalty Pharma's Total Non-Current Liabilities (Quarterly) stood at $7.3 billion in 2022, then dropped by 13.57% to $6.3 billion in 2023, then rose by 24.96% to $7.9 billion in 2024, then grew by 18.58% to $9.2 billion in 2025.
  • Its Total Non-Current Liabilities stands at $9.2 billion for Q3 2025, versus $8.4 billion for Q2 2025 and $7.8 billion for Q1 2025.